| |
| |
Find Out Which 11 Biotechs Stand Out From the Pack |
|
|
| |
Catalent is elated to share that its CEO and President, Alessandro Maselli, will have the honor of co-hosting this year’s Endpoints 11 award ceremony alongside Endpoints Founder and Editor, John Carroll.
Catalent congratulates all the nominees for this prestigious recognition and looks forward to shedding light on industry-leading pioneers in healthcare. |
|
|
| |
In Other News: Catalent Congratulates its
Partners for Their Recent Approvals |
|
|
Regeneron Receives Two FDA Approvals |
|
|
Catalent congratulates Regeneron for their two recent FDA approvals: a treatment for patients suffering from wet age-related macular degeneration (WAMD), diabetic edema (DME), and diabetic retinopathy (DR); and the first treatment for Chaple disease, a rare hereditary disease that can cause potentially life-threatening gastrointestinal and cardiovascular symptoms. Catalent stands ready in helping to manufacture these products in support of their patients in need. |
|
|
| |
Sarepta’s First FDA-Approved Gene Therapy Treatment Administered |
|
|
Catalent congratulates Sarepta Therapeutics on the administration of the first commercial dose of the first FDA-approved gene therapy treatment for patients aged 4 to 5 years old with Duchenne Muscular Dystrophy. Catalent’s dedicated packaging team for advanced therapies was proud to help make the dose available to the first patients before they turned 6 and would no longer be eligible under the current label. |
|
|
| |
Looking to Connect at an Upcoming Event? |
|
|
We look forward to meeting you at some of our upcoming events to discuss your program needs. |
|
|
| |
| |
| |
Every Molecule has a challenge. We have a solution.
|
|
|
| |
or call +1 877 891 9609 to speak with one of our experts today!
|
|
|
